Sökning: id:"swepub:oai:lup.lub.lu.se:dd7ca7dc-2542-45a2-9926-9f88df5f56c8" >
Factor VIII therapy...
Factor VIII therapy for hemophilia A: current and future issues
-
Aledort, Louis (författare)
-
- Ljung, Rolf (författare)
- Lund University,Lunds universitet,Enheten för pediatrisk hematologi,Forskargrupper vid Lunds universitet,Paediatric Hematologic Research Group,Lund University Research Groups
-
Mann, Kenneth (författare)
-
visa fler...
-
Pipe, Steven (författare)
-
visa färre...
-
(creator_code:org_t)
- 2014-04-10
- 2014
- Engelska.
-
Ingår i: Expert Review of Hematology. - : Informa UK Limited. - 1747-4086 .- 1747-4094. ; 7:3, s. 373-385
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Hemophilia A is a congenital, recessive, X-linked bleeding disorder that is managed with infusions of plasma-derived or recombinant factor (F) VIII. The primary considerations in FVIII replacement therapy today are the: 1) immunogenicity of FVIII concentrates, 2) role of longer-acting FVIII products, 3) prophylactic use of FVIII in children and adults with severe hemophilia A, and 4) affordability and availability of FVIII products. Improving patient outcomes by increasing the use of FVIII prophylaxis, preventing or eliminating FVIII inhibitors, and expanding access to FVIII concentrates in developing countries are the major challenges confronting clinicians who care for patients with hemophilia A.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Nyckelord
- factor concentrate
- FVIII
- gene therapy
- genetics
- hemophilia A
- immunogenicity
- longer
- acting FVIII
- prophylaxis
Publikations- och innehållstyp
- for (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas